Nandrolone decanoate
Deca-durabolin (nandrolone decanoate) is a small molecule pharmaceutical. Nandrolone decanoate was first approved as Nandrolone decanoate on 1983-09-28. It is used to treat anemia and breast neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nandrolone decanoate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DECA-DURABOLIN | Woodward Pharma Services | N-013132 DISCN | 1986-06-12 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nandrolone decanoate | 2007-02-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
| anemia | HP_0001903 | D000740 | D64.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J2320 | Injection, nandrolone decanoate, up to 50 mg |
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | 2 | — | — | 1 | — | 3 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | — | — | 1 | — | 1 |
| Ovarian reserve | D065851 | EFO_0004770 | — | — | — | — | 1 | — | 1 |
| Femoracetabular impingement | D057925 | — | — | — | — | — | 1 | — | 1 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Burns | D002056 | — | T30.0 | — | 2 | 2 | — | — | 2 |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 1 | 1 | 1 | — | — | 2 |
| Pancytopenia | D010198 | HP_0001876 | D61.81 | 1 | 1 | 1 | — | — | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | — | — | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | 1 | — | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 1 | — | — | 1 | 2 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | 1 | — | — | — | 1 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | 1 | — | — | — | 1 |
| Fibrosis | D005355 | — | — | 1 | 1 | — | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | 1 | 1 | — | — | — | 1 |
| Pulmonary fibrosis | D011658 | — | — | 1 | 1 | — | — | — | 1 |
| Bone marrow failure disorders | D000080983 | — | — | 1 | 1 | — | — | — | 1 |
| Telomere shortening | D059506 | — | — | 1 | 1 | — | — | — | 1 |
| Critical illness | D016638 | — | — | — | 1 | — | — | — | 1 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 3 | — | — | — | 1 | 4 |
| Cachexia | D002100 | HP_0004326 | R64 | 1 | — | — | — | 1 | 2 |
| Pharmacological phenomena | D000069437 | — | — | 1 | — | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Wasting syndrome | D019282 | — | — | 1 | — | — | — | — | 1 |
| Weight loss | D015431 | HP_0001824 | — | 1 | — | — | — | — | 1 |
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
| Hiv wasting syndrome | D019247 | EFO_0007312 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscular atrophy | D009133 | HP_0003202 | — | — | — | — | — | 1 | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | — | — | — | 1 | 1 |
| Muscle weakness | D018908 | HP_0001324 | — | — | — | — | — | 1 | 1 |
| Growth | D006128 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nandrolone decanoate |
| INN | — |
| Description | Nandrolone decanoate is a steroid ester. |
| Classification | Small molecule |
| Drug class | androgens; steroids (not prednisolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C |
Identifiers
| PDB | — |
| CAS-ID | 360-70-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200946 |
| ChEBI ID | 7467 |
| PubChem CID | 9677 |
| DrugBank | DB08804 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,064 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
198 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use